Access cutting-edge t-cell acute lymphoblastic leukemia treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Washington Dc location
Preparing your pre-screening questions…
Access t-cell acute lymphoblastic leukemia specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related t-cell acute lymphoblastic leukemia treatment provided free
Check if you qualify for this t-cell acute lymphoblastic leukemia clinical trial in Washington Dc, DC
No-Cost Study Care
Local to Washington Dc
Convenient for DC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
Sponsor: New York Medical College
Yes, this clinical trial (NCT04972942) has an active research site in Washington Dc, DC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for t-cell acute lymphoblastic leukemia treatment options in Washington Dc, DC, this clinical trial (NCT04972942) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced t-cell acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all t-cell acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.
See all leukemia clinical trials recruiting in Washington Dc — not just this study.
Browse Leukemia Trials in Washington Dc →